As the most common chromosomal disorder right now after Down syndrome, 22q is caused by a small missing part of chromosome 22. The deletion occurs about halfway down the chromosome at a location designated q11. 2. It is thought to be a midline condition, with physical symptoms aggregating palatal abnormalities, central defects, immune dysfunction, and esophageal/gastrointestinal problems, as well as debilitating behavioral and neuropsychiatric problems. Anxiety is one of the most common neuropsychiatric symptoms of 22q and researchers have found that in children with 22q, anxiety is linked to poorer adaptive behaviors such as self-care and communication skills than in daily life. Children with 22q also exhibit withdrawal behavior, ADHD, cognitive decline, and autism spectrum disorder that affects communication and social interaction. Later in life, they are at higher risk for intellectual ailments such as schizophrenia. 22q is estimated to occur in between one in 3,000 and one in 6,000 live births, suggesting that there are approximately 83,000 other people living with 22q in the United States. in Europe if the UK is included.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is a leader in innovative, pharmaceutically produced transdermal cannabinoid treatments for orphan neuropsychiatric disorders. We are committed to the lives of patients and their families living with serious chronic illnesses, in addition to fragile X syndrome, 22q11. 2 deletion syndrome, and autism spectrum disorders. Learn more about www. zynerba. com and follow us on Twitter on @ZynerbaPharma.
Cautionary Note On Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may, in certain instances, use terms such as “predicts”, “believes”, “prospective”, “proposes”, “continuesArray “”estimates”, “anticipates”, “expects”, “plans”, “intends”, “possibly”, “may also just”, “may also just”, “will”, “should”, or d other words that express the uncertainty of long-term events or effects to identify those forward-looking statements. These statements relate to vital factors, hazards and uncertainties that could cause actual events or effects to differ materially from the Company’s existing expectations. The Company’s Management’s expectations and, accordingly, any forward-looking statements contained in this press release may also be affected by dangers and uncertainties related to a number of other factors, including the following: cash and cash equivalents of the Company may not be enough to support your operating plan for the expected time; the Company’s expectations, projections and estimates regarding long-term expenses, revenues, capital requirements, eligibility for incentives and other tax credits, collectability and timing, and the availability and need for additional investments; the Company’s ability to offload additional investments to assist its clinical progression programs; the effects, charge and timing of the Company’s clinical progression programs, adding delays to such clinical trials similar to site registration or start-up; the clinical effects of the Company’s product applicants may not be reproduced or may continue to occur in further trials and may not support further progression in an express indication or at all; movements or recommendations of the US Food and Drug Administration, the European Medicines Agency, and other foreign regulatory agencies could affect the design, initiation, timing, continuation, and/or progress of clinical trials or result in the need for more clinical trials; the Company’s ability to download and obtain regulatory approval for applicants for its products and labeling in accordance with such approval; the company’s reliance on third parties to help it conduct pre-clinical and clinical trials for applicants of its products; delays, interruptions or disorder in the manufacture and origin of the Company’s requested products; the Company’s ability to market its applicant products; the duration and prospect of expanding markets for applicants of the Company’s products, and the Company’s ability to serve those markets; the Company’s ability to expand its sales and marketing capabilities, alone or with prospective long-term employees; the rate and extent of market acceptance of applicants for the Company’s products; the Company’s expectations related to its ability to properly download and maintain sufficient intellectual asset coverage for applicants of its products; the extent to which physical care outbreaks and other communicable disease outbreaks, in addition to COVID-19, may also disrupt our operations or have adverse effects on our business and monetary conditions; and the extent to which inflation or global political savvy, in addition to political savvy, would possibly have an effect on our business operations or monetary condition. This list is not exhaustive and these and other hazards are described in the Company’s periodic reports, adding the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. , filed with or provided to the Securities and Exchange Commission and available at www. sec. gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no legal responsibility to update any forward-looking statements, whether as a result of new information, long-term events or otherwise, after the date of this news release.
Contact
Peter VozzoICR WestwickeOffice: 443. 213. 0505Cellphone: 443. 377. 4767Peter. Vozzo@Westwicke. com
© 2022 Benzinga. com. Benzinga provides investment advice. All rights reserved.